BMS5121458 free base · Synonyms: Dapagliflozin

BMS512148 is a potent, selective renal sodium-dependent glucose cotransporter 2 inhibitor.

For research use only. Not for human or veterinary use.

Target SGLT

Research area Metabolic Disease Cancer

Purity >99.5% Stock Inquire

Data Sheet SDS COA

BMS5121458 structure

CAS No.: 461432-26-8

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
5 g	USD 280.00	BP-02074-5g	In stock	Get quote
10 g	USD 440.00	BP-02074-100g	In stock	Get quote
25 g	USD 890.00	—	In stock	Get quote

Need another size or custom synthesis? Request a quote.

Description

BMS512148 (Dapagliflozin) is a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor.

Biological activity

In Vitro Dapagliflozin (0-10 μM；24 hours) significantly increases the cell survival in hypoxic HK2 cell in a dose-dependent manner. Dapagliflozin (0-10 μM；2 hours) increases the HIF1 expression, increases AMPK and EKR phosphorylation in hypoxic HK2 cells, but shows no effect on the phosphorylation of AMPK and ERK in normoxic HK2 cells. In Vivo Dapagliflozin (oral administration; 10 mg/kg) causes a marked increase in urinary glucose in SGLT2i-mice, suppresses BAT thermogenesis by reducing sympathetic nerve activity and enhances hepatic gluconeogenesis and glycogenolysis.

Identifiers

SMILES: CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1
InChIKey: JVHXJTBJCFBINQ-ADAARDCZSA-N

Specifications

MW (average): 408.8730
Formula: C₂₁H₂₅ClO₆
CAS No.: 461432-26-8
Physical state: Other
Color: white to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder 4℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

Documents

References

[1]. Pedersen MG, et al. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. Sci Rep. 2016 Aug 18;6:31214.

[2]. Chiba Y, et al. Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice. PLoS One. 2016 Mar 10;11(3):e0150756.

[3]. Chang YK, et al. Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury. PLoS One. 2016 Jul 8;11(7):e0158810.

[4]. Meng, Wei et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Journal of medicinal chemistry vol. 51,5 (2008): 1145-9.

Same research area

Search Metabolic Disease